Publisher
Springer Science and Business Media LLC
Reference12 articles.
1. Forsaa EB, Larsen JP, Wentzel-Larsen T, et al. A 12-year population-based study of psychosis in Parkinson disease. Arch Neurol. 2010;67(8):996–1001.
2. Acadia Pharmaceuticals. ACADIA Pharmaceuticals and Biovail form collaboration to develop and commercialize pimavanserin in North America [media release]. 4 May 2009. http://www.acadia-pharm.com .
3. Acadia Pharmaceuticals Inc. ACADIA Pharmaceuticals enters agreement with Biovail to conclude collaboration and regain North American rights to pimavanserin [media release]. 28 Oct 2010. http://www.acadia-pharm.com .
4. Vanover KE, Weiner DM, Makhay M, et al. Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2- methylpropyloxy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine2A receptor inverse agonist. J Pharmacol Exp Ther. 2006;317(2):910–8.
5. Vanover KE, Robbins-Weilert D, Wilbraham DG, et al. Pharmacokinetics, tolerability, and safety of ACP-103 following single or multiple oral dose administration in healthy volunteers. J Clin Pharmacol. 2007;47(6):704–14.
Cited by
27 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献